{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:34:29Z","timestamp":1793144069351,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhltopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHLT Open"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jhlto.2024.100152","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:42:06Z","timestamp":1724463726000},"page":"100152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Circulating biomarkers in pulmonary arterial hypertension: State-of-the-art review and future directions"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-6262","authenticated-orcid":false,"given":"Salaheldin","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"R\u00e5degran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhlto.2024.100152_bib1","doi-asserted-by":"crossref","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jhlto.2024.100152_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020957234","article-title":"Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension","volume":"10","author":"Hemnes","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib5","first-page":"3618","article-title":"ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Marc","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14017431.2016.1185532","article-title":"Characteristics and survival of adult Swedish PAH and CTEPH patients 2000\u20132014","volume":"50","author":"R\u00e5degran","year":"2016","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.jhlto.2024.100152_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ijcard.2015.11.001","article-title":"Incidence and prevalence of pulmonary arterial hypertension in Germany","volume":"203","author":"Hoeper","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1378\/chest.15-0300","article-title":"Five-year outcomes of patients enrolled in the REVEAL Registry","volume":"148","author":"Farber","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/resp.13768","article-title":"Diagnostic delay in pulmonary arterial hypertension: insights from the Australian and New Zealand pulmonary hypertension registry","volume":"25","author":"Khou","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.jhlto.2024.100152_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12190","article-title":"Societal costs associated with pulmonary arterial hypertension: a study utilizing linked national registries","volume":"13","author":"Runheim","year":"2023","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17534666231218886","article-title":"The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey","volume":"18","author":"Small","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jhlto.2024.100152_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jhlto.2024.100152_bib17","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Co-published by National Institutes of Health (US), Bethesda (MD); 2016 Jan 28 [Updated 2020 Nov 16]."},{"key":"10.1016\/j.jhlto.2024.100152_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2213-2600(17)30161-3","article-title":"Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study","volume":"5","author":"Rhodes","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.chest.2022.08.2230","article-title":"Metabolomic profiles differentiate scleroderma-PAH from idiopathic PAH and correspond with worsened functional capacity","volume":"163","author":"Alotaibi","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib20","first-page":"L836","article-title":"Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension","volume":"324","author":"Simpson","year":"2023","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.05.014","article-title":"Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension","volume":"175","author":"Zhang","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894020931317","article-title":"Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification","volume":"10","author":"Bouzina","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","article-title":"Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension","volume":"147","author":"Guignabert","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jhlto.2024.100152_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20458940211059712","article-title":"Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension","volume":"11","author":"Ahmed","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1440-1681.12796","article-title":"Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension","volume":"44","author":"Li","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijcard.2021.10.136","article-title":"Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension","volume":"345","author":"Ahmed","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12269","article-title":"Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension","volume":"13","author":"Arvidsson","year":"2023","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.healun.2021.10.018","article-title":"Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters","volume":"41","author":"Yogeswaran","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100152_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.01232-2022","article-title":"Cytokines as prognostic biomarkers in pulmonary arterial hypertension","volume":"61","author":"Boucly","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/medicina59040748","article-title":"Prognostic value for mortality of plasma bioactive adrenomedullin in patients with pulmonary arterial hypertension: a sub analysis of the biomarker study in the COHARD-PH Registry","volume":"59","author":"Hartopo","year":"2023","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1016\/j.jhlto.2024.100152_bib32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/rccm.201807-1236OC","article-title":"Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension","volume":"199","author":"Nikolic","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.chest.2018.01.009","article-title":"Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: data from the REVEAL Registry","volume":"154","author":"Frantz","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1183\/09031936.00067011","article-title":"Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension","volume":"39","author":"Heresi","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib35","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/art.40534","article-title":"CCL21 as a potential serum biomarker for pulmonary arterial hypertension in systemic sclerosis","volume":"70","author":"Hoffmann-Vold","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jhlto.2024.100152_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/CIRCULATIONAHA.121.056719","article-title":"Plasma cell-free DNA predicts survival and maps specific sources of injury in pulmonary arterial hypertension","volume":"146","author":"Brusca","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jhlto.2024.100152_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/ard-2022-223237","article-title":"Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis","volume":"82","author":"Sanges","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhlto.2024.100152_bib38","first-page":"1","article-title":"Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension","volume":"9","author":"Zhang","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.02591-2020","article-title":"Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort","volume":"57","author":"Bauer","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1465-9921-14-130","article-title":"Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension","volume":"14","author":"Nickel","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00408-015-9802-y","article-title":"MR-proADM predicts exercise capacity and survival superior to other biomarkers in PH","volume":"193","author":"Kolditz","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.jhlto.2024.100152_bib42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1253\/circj.CJ-22-0172","article-title":"Plasma connective tissue growth factor as a biomarker of pulmonary arterial hypertension associated with congenital heart disease in adults","volume":"87","author":"Liu","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jhlto.2024.100152_bib43","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/crj.13421","article-title":"Potential of C-X-C motif chemokine ligand 1\/8\/10\/12 as diagnostic and prognostic biomarkers in idiopathic pulmonary arterial hypertension","volume":"15","author":"Li","year":"2021","journal-title":"Clin Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"Van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00378-2021","article-title":"The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension","volume":"7","author":"Simpson","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201409-1742OC","article-title":"Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension","volume":"191","author":"Damico","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib47","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1164\/rccm.202109-2106OC","article-title":"Mining the plasma proteome for insights into the molecular pathology of pulmonary arterial hypertension","volume":"205","author":"Harbaum","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019895446","article-title":"Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension","volume":"9","author":"Bouzina","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1679-8","article-title":"Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis","volume":"20","author":"Rice","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jhlto.2024.100152_bib50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/diagnostics10110857","article-title":"Galectin-3 plasma levels are associated with risk profiles in pulmonary arterial hypertension","volume":"10","author":"Scelsi","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.jhlto.2024.100152_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pul2.12195","article-title":"The diagnostic and prognostic value of growth differentiation factor-15 in systemic lupus erythematosus-associated pulmonary arterial hypertension","volume":"13","author":"Qian","year":"2023","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.580908","article-title":"Prognostic value of gamma-glutamyltransferase in male patients with idiopathic pulmonary arterial hypertension","volume":"7","author":"Lu","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pul2.12007","article-title":"Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival","volume":"12","author":"Yang","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib54","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1164\/rccm.201512-2498OC","article-title":"Hepatoma-derived growth factor predicts disease severity and survival in pulmonary arterial hypertension","volume":"194","author":"Yang","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1513\/AnnalsATS.201508-543OC","article-title":"Prognostic significance of biomarkers in pulmonary arterial hypertension","volume":"13","author":"Al-Naamani","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jhlto.2024.100152_bib56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/thoraxjnl-2018-212144","article-title":"Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension","volume":"74","author":"Harbaum","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jhlto.2024.100152_bib57","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.healun.2012.08.014","article-title":"HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance?","volume":"31","author":"Belly","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100152_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.chest.2018.04.022","article-title":"Serum chloride levels track with survival in patients with pulmonary arterial hypertension","volume":"154","author":"Naal","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015221","article-title":"Hypochloremia is a noninvasive predictor of mortality in pulmonary arterial hypertension","volume":"9","author":"Prins","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jhlto.2024.100152_bib60","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12931-021-01884-9","article-title":"Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension","volume":"22","author":"Xanthouli","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14017431.2020.1782977","article-title":"Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension","volume":"55","author":"Bouzina","year":"2020","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.jhlto.2024.100152_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01734-3","article-title":"Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival","volume":"18","author":"Yang","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-020-02218-8","article-title":"Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension","volume":"22","author":"Di Benedetto","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jhlto.2024.100152_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.healun.2022.10.026","article-title":"Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension","volume":"42","author":"Hirsch","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100152_bib65","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1513\/AnnalsATS.201410-463OC","article-title":"Interleukin-6 and tumor necrosis factor-\u03b1 are associated with quality of life-related symptoms in pulmonary arterial hypertension","volume":"12","author":"Matura","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jhlto.2024.100152_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/srep41650","article-title":"Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension","volume":"7","author":"Kope\u0107","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhlto.2024.100152_bib67","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1161\/CIRCULATIONAHA.120.047626","article-title":"Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension","author":"Omura","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jhlto.2024.100152_bib68","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.14937","article-title":"Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China","volume":"24","author":"Chen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00484-2022","article-title":"Computational platform for doctor\u2013artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study","volume":"9","author":"Kheyfets","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1164\/rccm.201205-0839OC","article-title":"Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension","volume":"187","author":"Rhodes","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03000605211002379","article-title":"Plasma exosomal miR-596: a novel biomarker predicts survival in patients with idiopathic pulmonary artery hypertension","volume":"49","author":"Huang","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103444","article-title":"A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach","volume":"69","author":"Errington","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhlto.2024.100152_bib73","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00408-017-0014-5","article-title":"Plasma MMP2\/TIMP4 ratio at follow-up assessment predicts disease progression of idiopathic pulmonary arterial hypertension","volume":"195","author":"Wetzl","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.jhlto.2024.100152_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045894019895414","article-title":"Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension","volume":"9","author":"Arvidsson","year":"2019","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib75","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/13993003.00245-2016","article-title":"Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension","volume":"48","author":"Zhang","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib76","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.202105-1118OC","article-title":"Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension","volume":"205","author":"Rhodes","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib77","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.118.039360","article-title":"Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension","volume":"139","author":"Chin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jhlto.2024.100152_bib78","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.chest.2019.12.037","article-title":"Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension","volume":"157","author":"Simpson","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib79","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1183\/13993003.00187-2015","article-title":"New potential diagnostic biomarkers for pulmonary hypertension","volume":"46","author":"Tiede","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib80","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/03009742.2017.1378714","article-title":"Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension","volume":"47","author":"Kylhammar","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jhlto.2024.100152_bib81","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ehf2.13184","article-title":"Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension","volume":"8","author":"Arvidsson","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jhlto.2024.100152_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00037-2019","article-title":"Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation","volume":"5","author":"S\u00e4leby","year":"2019","journal-title":"ERJ Open Research"},{"key":"10.1016\/j.jhlto.2024.100152_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00035-2018","article-title":"Low plasma stem cell factor combined with high transforming growth factor-\u03b1 identifies high-risk patients in pulmonary arterial hypertension","volume":"4","author":"Bouzina","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib84","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1164\/rccm.202003-0510OC","article-title":"Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome","volume":"202","author":"Rhodes","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib85","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/ATVBAHA.119.313267","article-title":"Diagnostic and prognostic significance of serum levels of SeP (selenoprotein P) in patients with pulmonary hypertension","volume":"39","author":"Kikuchi","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhlto.2024.100152_bib86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/clc.22262","article-title":"Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension","volume":"37","author":"Zheng","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib87","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12890-020-01309-1","article-title":"Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib88","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/resp.12283","article-title":"Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension","volume":"19","author":"Chen","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.jhlto.2024.100152_bib89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib90","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib91","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhlto.2024.100152_bib92","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease."},{"key":"10.1016\/j.jhlto.2024.100152_bib93","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"39","author":"Hoeper","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100152_bib94","article-title":"Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension","volume":"51","author":"Clara","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2021.12.001","article-title":"Lung Biomarkers: a new route for distinguishing pulmonary hypertension due to HFpEF from pulmonary arterial hypertension","volume":"351","author":"Guazzi","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jhlto.2024.100152_bib96","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.healun.2022.10.026","article-title":"Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension","volume":"42","author":"Hirsch","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100152_bib97","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1378\/chest.11-1267","article-title":"Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension","volume":"142","author":"Cracowski","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib98","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","article-title":"Prognostic versus predictive value of biomarkers in oncology","volume":"44","author":"Oldenhuis","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhlto.2024.100152_bib99","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","article-title":"Biomarker discovery and validation: statistical considerations","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jhlto.2024.100152_bib100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1165\/rcmb.2019-0056OC","article-title":"Functional impact of human genetic variants of COL18A1\/endostatin on pulmonary endothelium","volume":"62","author":"Goyanes","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jhlto.2024.100152_bib101","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12253","article-title":"Risk assessment in pulmonary arterial hypertension: a step towards clinical implementation based on the 2022 ESC\/ERS pulmonary hypertension guidelines","volume":"13","author":"Ahmed","year":"2023","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jhlto.2024.100152_bib103","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Marius","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib104","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Ath\u00e9na\u00efs","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib105","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/cc11466","article-title":"Prognostic utility and characterization of cell-free DNA in patients with severe sepsis","volume":"16","author":"Dwivedi","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jhlto.2024.100152_bib106","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1183\/13993003.00676-2015","article-title":"Circulating free DNA concentration is an independent prognostic biomarker in lung cancer","volume":"46","author":"Claire","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhlto.2024.100152_bib107","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.healun.2017.05.026","article-title":"Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation","volume":"36","author":"Agbor-Enoh","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jhlto.2024.100152_bib108","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib109","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2229-3485.86879","article-title":"Patient-reported outcomes: a new era in clinical research","volume":"2","author":"Deshpande","year":"2011","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.jhlto.2024.100152_bib110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1378\/chest.10-1166","article-title":"Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry","volume":"140","author":"Brown","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jhlto.2024.100152_bib111","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaccao.2020.07.006","article-title":"Primer on biomarker discovery in cardio-oncology: application of omics technologies","volume":"2","author":"Rhee","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jhlto.2024.100152_bib112","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.106.683110","article-title":"Benchmarks for the assessment of novel cardiovascular biomarkers","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jhlto.2024.100152_bib113","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/nat.2020.0865","article-title":"Researcher's perceptions on publishing \u201cnegative\u201d results and open access","volume":"31","author":"Echevarr\u00eda","year":"2020","journal-title":"Nucl Acid Therap"},{"key":"10.1016\/j.jhlto.2024.100152_bib114","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/bib\/bbw114","article-title":"Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences","volume":"19","author":"Manzoni","year":"2018","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.jhlto.2024.100152_bib115","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1164\/rccm.202201-0040ED","article-title":"Prime time for proteomics in pulmonary arterial hypertension risk assessment?","volume":"205","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib116","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1164\/rccm.202203-0537ED","article-title":"Promises and pitfalls of multiomics approaches to pulmonary arterial hypertension","volume":"205","author":"Simpson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhlto.2024.100152_bib117","unstructured":"Biomarker qualification: evidentiary framework. Draft Guidance for Industry and FDA Staff, 2018, FDA Center for Drug Evaluation and Research. Docket number: FDA-2018-D-426. https:\/\/regulations.gov\/document\/FDA-2018-D-4267-0002."}],"container-title":["JHLT Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133424001010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950133424001010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:14:45Z","timestamp":1762654485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950133424001010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":117,"alternative-id":["S2950133424001010"],"URL":"https:\/\/doi.org\/10.1016\/j.jhlto.2024.100152","relation":{},"ISSN":["2950-1334"],"issn-type":[{"value":"2950-1334","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating biomarkers in pulmonary arterial hypertension: State-of-the-art review and future directions","name":"articletitle","label":"Article Title"},{"value":"JHLT Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhlto.2024.100152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}],"article-number":"100152"}}